Farzan Nima 4

What Happened

• Farzan Nima, a director of Keros Therapeutics (KROS), sold 2,625 shares in an open-market transaction on June 4, 2026. The reported weighted-average sale price was $10.73 per share, for total proceeds of approximately $28,166. This was a sale (S), which is often routine insider liquidity rather than a purchase signal.

Key Details

• Transaction date: 2026-06-04; Filing date: 2026-06-08 (filed within the required two business days).
• Price: weighted average $10.73; individual trade prices ranged from $10.61 to $10.89 per share.
• Shares sold: 2,625; total proceeds ≈ $28,166.
• Shares owned after transaction: Not disclosed in the provided filing summary.
• Footnotes: (F1) Sale executed pursuant to a Rule 10b5-1 trading plan adopted December 5, 2025. (F2) Reported price is a weighted average; the filer can provide a breakout of the number of shares sold at each price within the $10.61–$10.89 range upon request.
• Transaction code: S = Sale.

Context

• A 10b5-1 plan allows insiders to sell shares according to pre-set instructions, which can help show trades were planned in advance and not based on undisclosed material information. Such sales are typically considered routine insider liquidity and do not necessarily indicate management sentiment about the company.